Deng Wei, McKelvey Kelly J, Guller Anna, Fayzullin Alexey, Campbell Jared M, Clement Sandhya, Habibalahi Abbas, Wargocka Zofia, Liang Liuen, Shen Chao, Howell Viive Maarika, Engel Alexander Frank, Goldys Ewa M
ARC Centre of Excellence for Nanoscale Biophotonics, Graduate School of Biomedical Engineering, University of New South Wales, Kensington, New South Wales 2052, Australia.
Bill Walsh Translational Cancer Research Laboratory, The Northern Clinical School, Faculty of Medicine and Health, The University of Sydney and Northern Sydney Local Health District Research (Kolling Institute), St Leonards, New South Wales 2065, Australia.
ACS Cent Sci. 2020 May 27;6(5):715-726. doi: 10.1021/acscentsci.9b01121. Epub 2020 Apr 24.
In this work, we brought together two existing clinical techniques used in cancer treatment-X-ray radiation and photodynamic therapy (PDT), whose combination termed X-PDT uniquely allows PDT to be therapeutically effective in deep tissue. To this end, we developed mitochondrially targeted biodegradable polymer poly(lactic--glycolic acid) nanocarriers incorporating a photosensitizer verteporfin, ultrasmall (2-5 nm) gold nanoparticles as radiation enhancers, and triphenylphosphonium acting as the mitochondrial targeting moiety. The average size of the nanocarriers was about 160 nm. Upon X-ray radiation our nanocarriers generated cytotoxic amounts of singlet oxygen within the mitochondria, triggering the loss of membrane potential and mitochondria-related apoptosis of cancer cells. Our X-PDT strategy effectively controlled tumor growth with only a fraction of radiotherapy dose (4 Gy) and improved the survival rate of a mouse model bearing colorectal cancer cells. data indicate that our X-PDT treatment is cytoreductive, antiproliferative, and profibrotic. The nanocarriers induce radiosensitization effectively, which makes it possible to amplify the effects of radiation. A radiation dose of 4 Gy combined with our nanocarriers allows equivalent control of tumor growth as 12 Gy of radiation, but with greatly reduced radiation side effects (significant weight loss and resultant death).
在这项工作中,我们将癌症治疗中现有的两种临床技术——X射线辐射和光动力疗法(PDT)结合在一起,二者结合形成的X-PDT能够使PDT在深部组织中产生治疗效果。为此,我们开发了线粒体靶向的可生物降解聚合物聚乳酸-乙醇酸纳米载体,其包含光敏剂维替泊芬、作为辐射增强剂的超小(2-5纳米)金纳米颗粒以及作为线粒体靶向部分的三苯基膦。纳米载体的平均尺寸约为160纳米。在X射线辐射下,我们的纳米载体在线粒体内产生细胞毒性水平的单线态氧,引发膜电位丧失和癌细胞的线粒体相关凋亡。我们的X-PDT策略仅用一小部分放疗剂量(4 Gy)就能有效控制肿瘤生长,并提高了携带结肠癌细胞的小鼠模型的存活率。数据表明,我们的X-PDT治疗具有细胞减灭、抗增殖和抗纤维化作用。纳米载体能有效诱导放射增敏,从而放大辐射效果。4 Gy的辐射剂量与我们的纳米载体相结合,对肿瘤生长的控制效果等同于12 Gy的辐射,但辐射副作用(显著体重减轻及由此导致的死亡)大大降低。